Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IFOM ETS - The AIRC Institute of Molecular Oncology
Accent Therapeutics
Vividion Therapeutics, Inc.
Nimbus Therapeutics
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
Marengo Therapeutics, Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Gruppo Oncologico del Nord-Ovest